Dr Reddys Laboratories Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Record revenue, NRT-driven: Consolidated revenue hit Rs. 8,359 crores, up 16% YoY, but the first-time consolidation of the NRT acquisition contributed Rs. 605 crores; underlying growth was 7.5% YoY with a 3% QoQ decline.
• US generics face a reset: North America revenue was flat YoY and fell 10% QoQ as price erosion and competition in Icosapent and Suboxone weighed on the base business, while Revlimid sales are expected to decline materially after September/October 2025.
• Margins compressed on investment: EBITDA margin fell 176 bps YoY to 27.5% as SG&A and R&D spend both rose ~20% YoY, funding NRT integration, new business initiatives, and complex generics. Management is comfortable with 25% EBITDA.
• The post-Revlimid growth bridge is taking shape: Management pointed to four levers: base market growth, productivity, special products like Semaglutide and Abatacept, and business development, with Semaglutide positioned as a significant but not singular replacement.
• What to watch next quarter: The pace of recovery in India's Cardiac and Gastro segments, any update on the USFDA Form 483 resolution at CTO-2, and the trajectory of US base business erosion ahead of the Revlimid cliff.

US Generics: Erosion, the Revlimid Cliff, and the Pipeline

• Base business under pressure: The US base business, excluding Revlimid, declined due to continued competition in Icosapent and Suboxone, where rivals entered 6-9 months ago, triggering a combination of market share loss and price erosion.
• Revlimid timeline is now explicit: Management stated it likely will not sell at current pricing levels past September/October of calendar 2025; until then, behavior is expected to be similar to the last couple of years.
• The fill-in pipeline: The company expects 15-20 product approvals in the US this fiscal year, in addition to Iron Sucrose, which received a CRL on the API side and will be delayed.
• Denosumab as a strategic bridge: Filed in both the US and Europe, Denosumab is expected to launch approximately 12 months from its December US submission and 14-15 months from its October European submission. The product is designed to build the commercial team and physician relationships that will later accelerate the Abatacept launch, since both target the same segments and doctors.

Erez Israeli: "Denosumab is actually supposed to facilitate Abatacept launch because the two products are going for the same segments and, give or take, to the same type of doctors. So it was also the strategic rationale of why to license the product. We wanted to create the team and the capability in the marketplace, to be able to then gain more or faster market share on Abatacept."

Semaglutide: The Long Bet

• A decade in the making: The company has been working on this project, including capacity, for 10 years, well before the product's blockbuster potential was clear. It is now fully integrated for all stages of API, from peptides using basic building blocks, and formulation, and is buying the device.
• Market opening sequence: Markets open in sequence starting in 2026, with Canada, India, and Brazil the most notable among roughly 80 primarily emerging markets with no patent protection. In Canada, Ozempic's patent expires January 2026, and the company believes it is positioned to secure approval for that window, with a normal 12-14 month review timeline.
• Go-to-market is multi-pronged: The strategy spans B2B and B2C, combining API sales, finished dose sales, and marketing through global licensing partners. Oral semaglutide will follow, typically 12-18 months after the injectable in most markets, and the company plans to be Day 1 wherever possible.
• Sizing the opportunity remains opaque: Management declined to indicate addressable market share, citing uncertainty about the competitive field, and deflected a question on whether Semaglutide could match Revlimid's North America contribution, emphasizing it is one lever among several, not a one-for-one replacement.

Erez Israeli: "It's not one silver bullet. We highlighted specifically Semaglutide at that time, because of the timing in which this product is going to affect, and I'm happy that you guys picked it up. But it's not that Semaglutide will replace Lenalidomide. All the business levers will have to grow."

NRT Acquisition: Integration and Investment

• First quarter of consolidation: The acquired Nicotine Replacement Therapy business contributed Rs. 605 crores in revenue, pushing the company to its highest-ever quarterly top line and EBITDA. The portfolio carries a PBT percentage around 21%, and management expects 20-plus digit EBITDA to continue.
• Transition services underway: Seamless integration will happen in phases starting April 2025. During the transition, seller Haleon will provide distribution and related services across all markets. The company has an agreement with Haleon on investment levels during this period and plans to invest more over the 12-14 months before full integration, rather than waiting.
• Growth is back-end loaded: Real growth is expected post-integration, but the company is not deferring investment. There is no plan for a multi-year investment period before profitability; the business will remain profitable while investment scales.

Erez Israeli: "The real growth will come post this integration, but we are going to invest more also in this 12 to 14 months of the time that we get those markets. We are not waiting for that."

India and Emerging Markets: Pockets of Softness

• India delivered double-digit growth, but with a split: Overall India revenue grew 14% YoY to Rs. 1,346 crores, benefiting from a broad portfolio, in-licensed vaccines, and new launches. Excluding vaccines, growth was 5%, as select brands in Cardiac and Gastro-intestinal therapy areas saw a slower pace.
• Recovery is staggered: The Gastro-intestinal segment is expected to recover relatively soon, while Cardiovascular may take an additional quarter as more adjustments are needed. Management is confident the business will return to market-leading growth in these therapy areas in coming quarters and sustain roughly 15% overall growth, outpacing the market at 7%.
• Emerging markets held up: The segment grew 12% YoY to Rs. 1,436 crores, driven by new product launches in Russia and Rest of the World markets. Russia grew 20% YoY in constant currency, with rouble volatility having only a small balance-sheet impact this quarter.
• Europe ex-NRT was a bright spot: Underlying growth of 22% YoY in INR terms was driven by existing products and new launches, more than offsetting price erosion. Management called this sustainable, supported by expansion from the top five countries to five more.

Erez Israeli: "Specifically to gastro, I have no doubt that it will come relatively soon. Cardiovascular may take an additional quarter as we need some more adjustments to do."

Margin and Cost Structure

• Investment drove the margin compression: EBITDA margin fell 176 bps YoY and 95 bps QoQ to 27.5%. SG&A rose 19% YoY on NRT integration, new business initiatives, capability building, and higher freight-driven logistics costs. R&D rose 20% YoY, directed at complex generics and biosimilars.
• SG&A is expected to hold at current levels: Management guided for SG&A to stay around 28% of sales, with a sequential uptick of Rs. 50-60 crores this quarter reflecting the first full quarter of NRT expenses, partially offset by the absence of the prior quarter's Rs. 52 crores exceptional stamp duty charge.
• The 25% EBITDA floor: Management stated it is very comfortable with 25% EBITDA, which it views as sufficient to deliver strong shareholder returns while funding investment in the system. R&D is guided to 8.5-9% of revenue for the full fiscal, and the normalized effective tax rate is around 25%.
• Below the line, a swing to net finance expense: Net finance income swung to a net expense of roughly Rs. 2 crores from net income of Rs. 96 crores last year, driven by unfavorable forex and lower interest income after the NRT acquisition consideration pay-out.

Regulatory and Pipeline Milestones

• USFDA Form 483 at CTO-2: The agency completed a GMP inspection at the Bollaram, Hyderabad facility in November and issued a Form 483 with seven observations. The company has responded within the stipulated timelines. Separately, it expects inspections at about five or six sites that have not been inspected for some time.
• Biosimilar progress: Rituximab secured Marketing Authorization in the UK. Abatacept completed a successful Phase I with rollout finished for all patients in very good timing; a filing is targeted for December 2025 if everything goes right, with a potential launch around January 2027, a timeline management described as aspirational. The subcutaneous version would follow at the beginning of 2028 per IP.
• Other pipeline items: Iron Sucrose received a CRL on the API side and will be delayed. DFD-29, on which the company is eligible for sales-based royalties, has now been approved.

Erez Israeli: "Like the Muslims say Inshallah. We hope for the best. Normally, it's about 12 months. So, let's hope. But let's say, from the patent point of view, January of '27 will be a great timeline, if we can achieve it."

Guidance & Commitments

Key Metrics